By Fineline Cube 
China-based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its wholly-owned subsidiary, Humanwell Innovation Pharmaceutical R&D Center (Wuhan) Co., Ltd., has received a Drug Clinical Trial Approval Notice from China’s National Medical Products Administration (NMPA) for HW241045 tablets. The approval permits clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF).
Drug Profile
HW241045 tablets are designated for the treatment of IPF. Currently, no drugs with the same target have been approved globally. Only two medications—nintedanib and pirfenidone—are approved for this disease. According to 2024 data from Menet, the annual sales of these two drugs in China were approximately RMB 1.2 billion and RMB 670 million, respectively.
R&D Investment
To date, the cumulative research and development investment for the HW241045 project is about RMB 23 million. This investment reflects Humanwell’s commitment to addressing unmet medical needs in the treatment of IPF and advancing innovative therapeutic options.-Fineline Info & Tech